Columbia Laboratories Announces Resignation of Chief Operating Officer.MIAMI--(BUSINESS WIRE)--Oct. 16, 1998--Columbia Laboratories Inc. (AMEX AMEX See: American Stock Exchange :COB) Friday announced that Nicholas A. Buoniconti, the company's Chief Operating Officer Chief Operating Officer (COO) The officer of a firm responsible for day-to-day management, usually the president or an executive vice-president. and Vice Chairman of its Board of Directors since April 1992 has decided to step down, effective immediately, from these positions to be able to devote more time to other interests. He also will not seek re-election as a director at the company's next annual meeting of shareholders. Buoniconti, a former All-Pro linebacker for the Miami Dolphins, expects to involve himself more extensively in, among other things, the work of the Miami Project to Cure Paralysis The Miami Project to Cure Paralysis is a research center dedicated to research in the field of paralysis and spinal cord injury, with the eventual object of finding a cure for paralyzing injuries. Based at the Leonard M. , of which he is a director, including its fund-raising efforts through the Marc Buoniconti Fund, named for his son. "I have enjoyed the challenges presented by serving as Columbia Laboratories' Chief Operating Officer, and I am proud to have contributed to the company during an important period in its history," said Buoniconti. "At this point, though, I feel I owe it to myself and others to focus more on other things. I look forward to spending more time helping the Miami Project achieve its aim of finding a cure for paralysis as soon as possible." William J. Bologna, Chairman of the company's Board of Directors, said, "Nick Buoniconti has contributed greatly to our success in his seven years with the company. We will miss Nick's involvement in the management of the company, but we are glad he will still be available to help us as needed. We wish him well in his other pursuits." Columbia Laboratories Inc. is a U.S.-based international pharmaceutical company, dedicated to research and development of women's health care products, including those intended to treat infertility, dysmenorrhea dysmenorrhea Pain or cramps before or during menstruation. In primary dysmenorrhea, caused by endocrine imbalances, severity varies widely. Irritability, fatigue, backache, or nausea may also occur. , endometriosis endometriosis (ĕn'dəmē'trē-ō`sĭs), a condition in which small pieces of the endometrium (the lining of the uterus) migrate to other places in the pelvic area. , hormonal deficiencies and the prevention of sexually transmitted diseases Sexually transmitted diseases Infections that are acquired and transmitted by sexual contact. Although virtually any infection may be transmitted during intimate contact, the term sexually transmitted disease is restricted to conditions that are largely . Columbia's research in reproductive endocrinology has also led to the development of product to treat "Andropause andropause /an·dro·pause/ (an´dro-pawz) a variable complex of symptoms, including decreased Leydig cell numbers and androgen production, occurring in men after middle age, purported to be analogous to menopause in women. " in men. Columbia's products primarily utilize the company's patented bioadhesive delivery technology. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion